List of top CLINICAL HAEMATOLOGY Questions on White Cell Disorders

Discuss the diagnosis and prognosis of triple-negative myelofibrosis (TN-MF).

How does it differ from triple-negative essential thrombocytosis in prognosis?

Briefly discuss the genomic landscape of TN-MF.

What are the evidence-based second-line therapies for PV patients?

In Philadelphia positive acute lymphoblastic leukemia (ALL), how is the choice of tyrosine kinase inhibitor (TKI) made?

Discuss the role of baseline tyrosine kinase domain mutation study in this scenario.

In an elderly patient with Philadelphia positive ALL, what are the chemotherapy-free treatment options?

Describe the risk stratification of polycythemia vera (PV) patients.

Discuss the options for PV therapy in an elderly patient >60 years of age.